Tricida, Inc. (TCDAQ)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -133.91M |
| Shares Out | n/a |
| EPS (ttm) | -2.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 251,865 |
| Open | 0.0160 |
| Previous Close | 0.0120 |
| Day's Range | 0.0090 - 0.0160 |
| 52-Week Range | 0.0050 - 0.0840 |
| Beta | n/a |
| Analysts | Sell |
| Price Target | n/a |
| Earnings Date | Mar 27, 2023 |
About TCDAQ
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy ... [Read more]
Financial Performance
Financial StatementsNews
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tricida, Inc.
Wilmington, Delaware--(Newsfile Corp. - February 8, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Tricida, Inc. (NASDAQ: TCDA) on behalf of stockh...
5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 10 most-shorted stocks as of November 2022
The difficult state of the macroeconomic environment in 2022 has had a negative impact on the performance of a number of equity investments. Worries about a recession and a bearish attitude among inve...
Tricida Announces Third Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key init...
Why Is Tricida (TCDA) Stock Down 90% Today?
Tricida (NASDAQ: TCDA) stock is falling on Monday following the release of poor results from a Phase 3 clinical trial. That trial covers the use of veverimer to treat patients suffering from metaboli...
Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer
SOUTH SAN FRANCISCO, Calif.
Tricida Announces $125 Million Debt Facility with Hercules Capital
SOUTH SAN FRANCISCO, Calif.
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA) on behalf of the Company's long-term investors.
Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) announced today that a late-breaking clinical trial abstract on the Phase 3, VALOR-CKD renal outcomes trial has been selected...
TRICIDA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigat...
Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a ...
TRICIDA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigat...
Tricida Announces Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida Announces Second Quarter 2022 Financial Results
Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on M...
Tricida Announces Administrative Stop of the VALOR-CKD Trial
Expects to Announce Top-Line Results Early in the Fourth Quarter of 2022 Expects to Announce Top-Line Results Early in the Fourth Quarter of 2022
Tricida Announces First Quarter 2022 Financial Results
Webcast Today at 4:30 pm Eastern Time Webcast Today at 4:30 pm Eastern Time
Tricida to Report First Quarter Financial Results and Host Conference Call and Webcast on Tuesday, May 10, 2022
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2022 financial results after the close of market on Tue...
Tricida to Present at the Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today that it will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, Ap...
Tricida Announces Fourth Quarter and Full Year 2021 Financial Results
Webcast Today at 4:30 pm Eastern Time
Tricida to Report Fourth Quarter Financial Results and Host Conference Call and Webcast on Tuesday, March 29, 2022
SOUTH SAN FRANCISCO, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2021 financial results after the close ...
Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug cand...
Tricida to Participate in Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug cand...
Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO
SAN DIEGO--(BUSINESS WIRE)--Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human ...
Tricida to Present at the 40th Annual J.P. Morgan Healthcare Conference and the H.C.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, Janua...